Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, ...

AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Vertex Pharma receives CHMP positive opinion for label expansion of Kaftrio in combination with ivacaftor: London Tuesday, March 4, 2025, 14:00 Hrs [IST] Vertex Pharmaceuticals, a ...

AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...